Incannex Healthcare Inc ADR (IXHL) Stock Price, Quote & News

Company Profile

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 61 4 0984 0786

Website: www.incannex.com

Address:

8 Century Circuit, Suite 105 Norwest, Sydney, Australia

RollTheDice369 Sep. 7 at 7:08 AM

$IXHL Shorts lost all of ammo and starting talking about Apnimed. You’re more into pushing fear and rumors than real investing

0 · Reply

HANR Sep. 7 at 7:03 AM

$IXHL Funny how every short seller clings to any straw. Apnimed has no Breakthrough and no regulatory protectionjust stretched-out results that mean nothing in front of the FDA. Incannex, on the other hand, has a full pipeline (OSA, GAD, RA) with Phase 2 results smashing expectations with 83% AHI reductionand that’s what opens the door to multi-billion dollar buyouts. What you fail to understand is simple: Big Pharma doesn’t buy “a study” like Apnimed, they buy therapeutic and regulatory monopoly. And that’s something only IXHL owns. Bottom line: you’re not trying to convince usyou’re trying to convince yourself before the short squeeze wipes out your position.

1 · Reply

Crewy77 Sep. 7 at 7:01 AM

$IXHL you really are getting more pathetic and desperate as the day goes on this isn’t normal behaviour

0 · Reply

ST3WPIDHO3 Sep. 7 at 6:36 AM

Ok...so you fumbled the bag Grow up with all that bitchassness ✌️ PSX-001 (Psi-GAD): Incannex reported positive Phase 2 results for its treatment of generalized anxiety disorder, with the trial meeting all key endpoints. IHL-42X for Obstructive Sleep Apnea (OSA): The company released positive patient-reported outcomes and topline efficacy data from its Phase 2 RePOSA trial. The data showed a significant reduction in the Apnoea-Hypopnoea Index (AHI) and a positive safety profile. Financial and Corporate News Share Buyback Program: Incannex authorized a $20 million share repurchase program, indicating confidence in the company's financial position. Financials: The company reported a strong cash position and reduced net losses for the third quarter of fiscal year 2025. FDA Engagement: Incannex is preparing for an End-of-Phase 2 meeting with the FDA to discuss the path forward to Phase 3 trials. Phase 3 planning for the IHL-42X drug is underway in AMERICA 🇺🇸 $IXHL

0 · Reply

MoreBags4Me Sep. 7 at 6:35 AM

$IXHL You're about 4 months to late trying to use this one to shake shares out. 🤣

0 · Reply

Kalvin1809 Sep. 7 at 6:27 AM

$IXHL Deserves to be at this price Management screwed us with its rug pull

0 · Reply

NeverCap Sep. 7 at 6:06 AM

$IXHL any catalyst this week ?

1 · Reply

DayTraderBatman Sep. 7 at 5:36 AM

$IXHL i have a tiny 1k bid in this looking to add when it pops. Hope soon, this is far to undervalued still.

0 · Reply

modrica3 Sep. 7 at 5:07 AM

$IXHL or like this

1 · Reply

modrica3 Sep. 7 at 5:06 AM

$IXHL his FUD is weak

0 · Reply

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

Aug 22, 2025, 8:00 AM EDT - 15 days ago

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

Aug 19, 2025, 4:29 PM EDT - 18 days ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update

Aug 8, 2025, 8:00 AM EDT - 4 weeks ago

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

Jul 31, 2025, 8:00 AM EDT - 5 weeks ago

Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term

Jul 30, 2025, 10:10 AM EDT - 5 weeks ago

Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial

Jul 30, 2025, 8:00 AM EDT - 5 weeks ago

Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X

Jul 25, 2025, 7:30 AM EDT - 6 weeks ago

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

Jun 24, 2025, 7:30 AM EDT - 2 months ago

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

Jun 18, 2025, 7:30 AM EDT - 2 months ago

Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X

Jun 17, 2025, 7:30 AM EDT - 2 months ago

Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy

Jun 12, 2025, 7:30 AM EDT - 3 months ago

Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Jun 3, 2025, 7:30 AM EDT - 3 months ago

Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

May 29, 2025, 7:30 AM EDT - 3 months ago

Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance

May 28, 2025, 4:21 PM EDT - 3 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025

May 28, 2025, 7:00 AM EDT - 3 months ago

Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results

May 20, 2025, 7:30 AM EDT - 3 months ago

Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution

May 16, 2025, 9:00 AM EDT - 4 months ago

Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants

May 15, 2025, 8:00 AM EDT - 4 months ago

Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

May 14, 2025, 4:14 PM EDT - 4 months ago

Incannex Healthcare (IXHL) Stock Soars Over 800%: What's Going On?

May 14, 2025, 8:00 AM EDT - 4 months ago

Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Apr 3, 2025, 7:30 AM EDT - 5 months ago

Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Mar 7, 2025, 2:10 PM EST - 6 months ago

Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules

Feb 18, 2025, 5:51 PM EST - 7 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025

Feb 14, 2025, 7:30 AM EST - 7 months ago

Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

Feb 4, 2025, 9:15 AM EST - 7 months ago

Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

Jan 23, 2025, 7:30 AM EST - 8 months ago

Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea

Dec 2, 2024, 4:48 PM EST - 9 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025

Nov 14, 2024, 4:05 PM EST - 10 months ago

Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates

Oct 24, 2024, 7:30 AM EDT - 11 months ago

Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

Oct 2, 2024, 4:50 PM EDT - 1 year ago

Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)

Sep 30, 2024, 4:01 PM EDT - 1 year ago

Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives

Aug 5, 2024, 7:30 AM EDT - 1 year ago

FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X

May 30, 2024, 7:30 AM EDT - 1 year ago

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

May 7, 2024, 7:30 AM EDT - 1 year ago

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder

May 1, 2024, 2:33 PM EDT - 1 year ago

Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)

Feb 16, 2024, 7:30 AM EST - 1 year ago

Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation

Feb 1, 2024, 7:30 AM EST - 1 year ago

Clarion Clinics Open for Psychedelic-Assisted Treatments

Jan 24, 2024, 4:05 PM EST - 1 year ago

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Jan 18, 2024, 8:22 AM EST - 1 year ago

Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences

Jan 17, 2024, 7:30 AM EST - 1 year ago

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Dec 21, 2023, 4:05 PM EST - 1 year ago

Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia

Dec 6, 2023, 7:30 AM EST - 1 year ago

Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

Nov 29, 2023, 1:40 PM EST - 1 year ago

Incannex Healthcare Announces Completion of its Redomiciliation to the United States

Nov 16, 2023, 8:30 AM EST - 1 year ago

Federal Court of Australia Approves Incannex's Re-Domiciliation and Lodgement of Court Orders With ASIC

Sep 8, 2023, 7:30 AM EDT - 2 years ago

Incannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023

Aug 24, 2023, 7:30 AM EDT - 2 years ago

Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD

Aug 22, 2023, 7:30 AM EDT - 2 years ago

Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed

RollTheDice369 Sep. 7 at 7:08 AM

$IXHL Shorts lost all of ammo and starting talking about Apnimed. You’re more into pushing fear and rumors than real investing

0 · Reply

HANR Sep. 7 at 7:03 AM

1 · Reply

Crewy77 Sep. 7 at 7:01 AM

$IXHL you really are getting more pathetic and desperate as the day goes on this isn’t normal behaviour

0 · Reply

ST3WPIDHO3 Sep. 7 at 6:36 AM

0 · Reply

MoreBags4Me Sep. 7 at 6:35 AM

$IXHL You're about 4 months to late trying to use this one to shake shares out. 🤣

0 · Reply

Kalvin1809 Sep. 7 at 6:27 AM

$IXHL Deserves to be at this price Management screwed us with its rug pull

0 · Reply

NeverCap Sep. 7 at 6:06 AM

$IXHL any catalyst this week ?

1 · Reply

DayTraderBatman Sep. 7 at 5:36 AM

$IXHL i have a tiny 1k bid in this looking to add when it pops. Hope soon, this is far to undervalued still.

0 · Reply

modrica3 Sep. 7 at 5:07 AM

$IXHL or like this

1 · Reply

modrica3 Sep. 7 at 5:06 AM

$IXHL his FUD is weak

0 · Reply

RaphaelRapoport Sep. 7 at 5:06 AM

$IXHL look a wild bear appeared. Quickly use idgaf. Highly effective. Good luck my dude. You can try and FUD but it’s pathetic. You’ve posted so much recently. Sorry your short position entry was dog shit and now you’re looking for an exit. That or you really just desperate for a few more $$ This ain’t the stock. You may win short term but this is a long term winning play. I’ll see you at any price but when this finishes and I’m cashing my $$ I’ll buy you a little goodie bag.

0 · Reply

Michaelthoaicaonguyen Sep. 7 at 4:00 AM

$IXHL $SKYE yes drenobinol have small and controlled amount of thc in it. Too little to have any adverse side effect. Look at Zoloft it causes mental breakdown and suicided and it still on the market. Yes SKYE focus is to loose weight to treat sleep apnea. You know how hard it is for a 300lb person to loose weight and how long that would take. Marijuana has proven to be very therapeutic to health. So much that the current administration is considering to scale down the class for it. I’m not say that your point is wrong. What IXhl offer benefit out weigh the minimal risk. FDA would not grant clearance to phase 3 if they think or know the psychological damage IXHL could cause. FDA expert to review and look at phase 2 (83% effective with minimal side effect) to grant clearance to phase 3. To say that Skye would revolutionize weigh lost I agree but IXHL is the key for sleep apnea patients in terms of breathing and REM sleeping.

2 · Reply

ST3WPIDHO3 Sep. 7 at 4:00 AM

Annnd this is you right now 😆 😂 $IXHL

1 · Reply

NOOBofNASDAQ Sep. 7 at 3:45 AM

$IXHL don’t listen to the rookie

1 · Reply

BIOTECH_GURU Sep. 7 at 3:38 AM

$IXHL $SKYE Very astute question. 1. CBD receptor modulators will ALWAYS be limited by psychiatric adverse effects. This is a big red flag for ixhl because dronabinol has been shown to reduce osa events since 2017, but ae are a huge barrierm 2. Skye formulated their drug as a large molecule that doesn't cross the blood brain barrier. Focusing on the peripheral receptors and ultimately eliminating the cns adverse events. 3. Different markets, different combinations. Market for OSA and obesity are $5B vs $100B. And OSA is technically treated by weight loss drugs even though the indication isn't here yet. Meaning skye drug will treat osa and obesity while ixhl drug will only be targetting osa. I think ixhl has very little chance for fda approval due to ae and their approach being faulty.

1 · Reply

Jahcho Sep. 7 at 3:30 AM

$IXHL Funnnny!!!!! Lol. Stomach hurting from laughing. Good one!

1 · Reply

Market Cap	15.45M
Revenue (ttm)	10,000.00
Net Income (ttm)	-18.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-184,600.00%
Debt to Equity Ratio	3.89

Volume	51,125,602
Avg Vol	149,735,891
Day's Range	N/A - N/A
Shares Out	29.43M
Stochastic %K	4%
Beta	7.66
Analysts	Hold
Price Target	N/A